OraSure Gets FDA Approval and Four Post-Holiday Analyst Alerts

Computer Programs & Systems Inc. (NASDAQ:CPSI) estimates have been reduced by Piper Jaffray following channel checks indicating an increase of preference toward based SaaS solutions at small hospitals and that the company did not add any new customers during Q2. The firm maintains a Neutral rating but dropped its price target from $62 to $56 on the stock.

Don’t Miss: Is Apple Augmenting Reality?

Accretive Health, Inc.’s (NYSE:AH) filing late Tuesday indicates that the company and Ascensions have decreased the time period necessary to notify contract non-renewal to 154 days from 180 days. This creates concerns regarding Accretive Health’s largest customer, and Piper claims that if Ascension does not renew, ore either renews with stringent terms, Accretive Health’s estimates would take a large cut. The firm keeps an Underweight rating on the shares.

The McGraw-Hill Companies, Inc. (NYSE:MHP): Following Hellman & Freidman’s $1.7B payment for the acquisitions of UK-based advisory business Wood Mackenzie, Jefferies states that the fact that McGraw-Hill did not enter into a bidding war for the asset should be amended. The firm gives the shares a Buy rating and a $54 price target on shares.

OraSure Technologies Inc. (NASDAQ:OSUR): According to ThinkEquity, because OraSure’s over-the-counter HIV test was approved before expected, it should stongly impact the company’s Q4 revenues. Shares have a Buy rating with a $17 price target.

Wolverine World Wide Inc. (NYSE:WWW) Q2 results on July 10 should be mostly in-line with expectations, says Jefferies since it believes European risks were reflected in management’s guidance. The firm maintains a Buy rating and a $49 price target on the shares.

Don’t Miss: Wall Street Brief: Apple Bites the Bullet, But Best Buy is Still a Fan.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:   , , , , , , ,